Karyopharm Therapeutics (KPTI) PT Raised to $25 at Baird After Xpovio Approval
Tweet Send to a Friend
Baird analyst Michael Ulz raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $25.00 (from $15.00) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
